# A Split‐Scar Study: Study of Surgical Scar Using Exosomes

**Authors:** Kyung Hwan Jeong, Kui Young Park, Dong‐Woo Jung

PMC · DOI: 10.1111/jocd.70756 · Journal of Cosmetic Dermatology · 2026-02-26

## TL;DR

This study shows that exosomes can improve the appearance of surgical scars, especially in pigmentation and texture.

## Contribution

The study demonstrates the efficacy of ASC-exosomes in postoperative scar improvement through a split-scar design.

## Key findings

- ASC-exosome treatment improved pigmentation, pliability, and relief in scar assessment scales.
- Improvements in scar quality were visible as early as week 2 and persisted through week 8.
- One-year follow-up showed better scar height and thickness on the exosome-treated side.

## Abstract

Exosomes have emerged as a promising therapeutic agent for various dermatological conditions such as acne, atopic dermatitis, and wound healing. This study aims to evaluate exosome's efficacy in improving postoperative scars.

Ten patients underwent revision rhinoplasty with autologous costal cartilage, each with a 3 cm anterior chest incision scar were enrolled. Scars (mean 4.3 months postoperatively) were divided into medial and lateral halves; one half was treated with ASC‐Exosome (experimental) and the other with hyaluronic acid (control). Outcomes were assessed using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS).

The experimental side treated with ASC‐Exosome demonstrated improvements compared to the control side. Pigmentation improved significantly in the Observer Scar Assessment Scale (OSAS) group from week 3 onward, though no consistent changes were observed on the VSS. Pliability showed significant improvement in both OSAS and VSS, beginning at week 3 and persisting through week 8. Relief also improved in the OSAS group from weeks 4 to 8. While no vascularity differences were detected, one‐year follow‐up photographs confirmed superior improvements in scar height and thickness on the exosome‐treated side. Patient Scar Assessment Scale (PSAS) indicated significant improvements in scar color by week 4, stiffness by week 3, and thickness by week 2. Irregularity showed significant differences at week 4 and week 8. No significant differences were noted in pain or itching between the sides.

Exosomes significantly improved scar quality, particularly pigmentation, pliability, and relief, and can represent a valuable option for postoperative scar management.

## Linked entities

- **Diseases:** acne (MONDO:0011438), atopic dermatitis (MONDO:0004980)

## Full-text entities

- **Genes:** PYCARD (PYD and CARD domain containing) [NCBI Gene 29108] {aka ASC, CARD5, TMS, TMS-1, TMS1}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, COL3A1 (collagen type III alpha 1 chain) [NCBI Gene 1281] {aka EDS4A, EDSVASC, PMGEDSV}, COL9A2 (collagen type IX alpha 2 chain) [NCBI Gene 1298] {aka DJ39G22.4, EDM2, MED, STL5}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, TRP-AGG2-5 (tRNA-Pro (anticodon AGG) 2-5) [NCBI Gene 7217] {aka TRNAP1, TRNP1, TRP-AGG2-3, TRP1}
- **Diseases:** hypertrophic (MESH:D002312), atopic dermatitis (MESH:D003876), acne (MESH:D000152), hyperpigmentation (MESH:D017495), skin lesions (MESH:D012871), Wound dehiscence (MESH:D013529), pain (MESH:D010146), fibrosis (MESH:D005355), inflammation (MESH:D007249), Pigmentation (MESH:D010859), OSAS (MESH:D002921), itching (MESH:D011537)
- **Chemicals:** melanin (MESH:D008543), steroid (MESH:D013256), CO2 (MESH:D002245), triamcinolone (MESH:D014221), HA (MESH:D006820), silicone (MESH:D012828)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945872/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945872/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945872/full.md

---
Source: https://tomesphere.com/paper/PMC12945872